CARsgen Therapeutics Holdings Ltd. has announced that the abstract of their research results on SATRI-CEL for adjuvant therapy of pancreatic cancer has been accepted for poster presentation at the ESMO Congress 2025. The study focuses on the application of SATRI-CEL, a CAR T-cell therapy, aimed at targeting solid tumors such as pancreatic cancer. The presentation is scheduled for a future date, as part of CARsgen's ongoing efforts to advance their product pipeline addressing challenges faced by existing CAR T-cell therapies, including improving safety, enhancing efficacy, and reducing treatment costs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.